CSPC PHARMACEUT.GR. ADR4 Asset Resilience Ratio
CSPC PHARMACEUT.GR. ADR4 asset resilience ratio. CSPC PHARMACEUT.GR. ADR4 (CVGU) has an Asset Resilience Ratio of 15.25% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of CSPC PHARMACEUT.GR. ADR4 to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CSPC PHARMACEUT.GR. ADR4 (2021–2025)
Asset resilience ratio of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025. This chart shows how CSPC PHARMACEUT.GR. ADR4's Asset Resilience Ratio has changed over time. Read total liabilities of CSPC PHARMACEUT.GR. ADR4 for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CSPC PHARMACEUT.GR. ADR4's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is CSPC PHARMACEUT.GR. ADR4's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €8.54 Billion | 15.25% |
| Total Liquid Assets | €8.54 Billion | 15.25% |
Asset Resilience Insights
- Good Liquidity Position: CSPC PHARMACEUT.GR. ADR4 maintains a healthy 15.25% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CSPC PHARMACEUT.GR. ADR4 Industry Peers by Asset Resilience Ratio
Compare CSPC PHARMACEUT.GR. ADR4's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
CSPC PHARMACEUT.GR. ADR4 Asset Resilience Ratio by Year (2021–2025)
CSPC PHARMACEUT.GR. ADR4 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for CSPC PHARMACEUT.GR. ADR4.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.94% | €2.78 Billion ≈ $3.25 Billion |
€46.70 Billion ≈ $54.59 Billion |
+2.63pp |
| 2024-12-31 | 3.32% | €1.47 Billion ≈ $1.72 Billion |
€44.39 Billion ≈ $51.90 Billion |
+0.99pp |
| 2023-12-31 | 2.33% | €1.08 Billion ≈ $1.26 Billion |
€46.28 Billion ≈ $54.11 Billion |
-6.23pp |
| 2022-12-31 | 8.56% | €3.57 Billion ≈ $4.18 Billion |
€41.77 Billion ≈ $48.83 Billion |
+4.40pp |
| 2021-12-31 | 4.15% | €1.44 Billion ≈ $1.69 Billion |
€34.74 Billion ≈ $40.62 Billion |
-- |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more